"Pharmaceutical Headlines" 2020 "Biotech Mammoth" top 15 list.

(2020/09/29) Pfizer XELJANZ approved the fourth adaptive disease in the United States; new progress in liver cancer treatment; take you to the glass uric acid industry: 90% gross margin of the domestic top three collective landing A shares; Pfizer XELJANZ approved the fourth adaptive disorder in the United States; three major pharmaceutical enterprises in the field of blood products pattern or change ... (Click on the title, available in the original article) Pfizer XELJANZ in the United States approved the fourth adaptive disease 28, Pfizer announced that the United States FDA approved XELJANZ® for the treatment of active multi-joint disease in adolescents with idiopathic arthritis 2 years and older children and adolescents.
has previously been approved in the United States for three types of adaptive disorders: moderate to severe active RA patients after failure to use methotrexate; adult patients with active psoriasis arthritis after failure to use anti-rheumatoid drugs; and adult patients with moderate to severe active colitis after failure with tumor necrosis agent inhibitors.
: This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved for the treatment of pcJIA in the United States.
new advances in liver cancer treatment with the Medical Rubik's Cube! CD147 CAR-NK: Shown to be effective anti-tumor active hepatocellular carcinoma is one of the deadliest solid tumors in humans, and there is currently no effective treatment for this type of cancer.
first-line standard treatment drug Sorafinib (a multi-kinase inhibitor) is widely used in advanced hepatocellular carcinoma, but it has low efficacy and serious side effects.
among the many liver cancer therapies under development, CAR-modified immunocellular therapies are developing rapidly, and one of the major challenges is finding safe and effective targets.
: This method can provide treatment options for patients with liver cancer.
2020 "Biotech Mammoth" 15 list: from fighting COVID-19 to treating cancer today, the industry's best-known annual "Fierce Biotech's 2020 Fierce 15" list is hot.
In 2020, when the new crown epidemic sweeps the globe, Fierce Biotech has chosen not only a number of biotech companies that use cutting-edge technology to fight COVID-19, but also start-ups that are struggling with long-standing challenges.
: It's been a decade in a row.
"New Kangjie" to take you to know the glass uric acid industry: gross margin of 90% of the domestic top three collective landing A-share GEM medical first shares - Ameer on September 28 in the Shenzhen Stock Exchange GEM listing, securities code "300896", the issue price of 118.27 yuan / share, today's closing price of 340.10 yuan / share, the first day of listing up 187.56%.
: Pharmaceutical grade glass uric acid accounts for the largest proportion.
"E drug manager" three pharmaceutical central enterprises have all entered the field of blood products pattern or change with China Resources Pharmaceutical merger and acquisition of Boya biological intention is clear, China's three major pharmaceutical central enterprises have all entered the field of blood products.
If the merger is finalized, the industry believes that with the help of China Resources Pharmaceuticals' state-owned background and predictable government resources, the blood products sector may be changing, Boya Bio is expected to become the fifth "thousand-ton" plasma company after Hualan Bio, Temple of Heaven Biology, Shanghai Lais, Taibang Bio.
: China Resources Pharmaceuticals intends to take control of Boya Bio.
.